Durgical
EN
Open the app

Treating obesity: lifestyle, medicines and surgery

  • Follow-up and treatment

Losing even 5–10% of body weight improves sugar, blood pressure and the liver. Today's medicines and surgery can do far more, but only while they are continued.

Updated

What it is

Obesity is a chronic, relapsing disease, so treatment is long term and stepped by the severity of disease and its complications. Every plan starts with nutrition, physical activity, sleep and behaviour change. Medicines are added when BMI is 30 or more, or 27 or more with a weight-related complication (lower thresholds in Asian ancestry). Metabolic and bariatric surgery is the most effective treatment for severe obesity. The body defends its weight by raising hunger and lowering energy use after weight loss, which is why weight returns when treatment stops.

What to know

  • Benefits start early: 5% weight loss improves glucose, triglycerides and blood pressure; 10–15% improves fatty liver, sleep apnoea and joint pain.
  • Lifestyle: a sustained energy deficit, a healthy eating pattern the patient can keep, at least 150 minutes a week of moderate activity, resistance training and sleep.
  • GLP-1 receptor agonists (semaglutide, liraglutide) reduce appetite and slow gastric emptying; trials of the newer agents show average losses of around 15%.
  • Dual GIP/GLP-1 receptor agonists (tirzepatide) give larger average losses, around 20% in trials.
  • In people with cardiovascular disease and overweight without diabetes, semaglutide reduced major cardiovascular events.
  • Other options: lipase inhibitor (orlistat), phentermine-topiramate, naltrexone-bupropion; setmelanotide for rare leptin–melanocortin pathway defects.
  • Incretin drugs: nausea and other gut effects are common; gallstones and pancreatitis can occur; avoid with personal or family history of medullary thyroid cancer or MEN2, and in pregnancy.
  • Surgery (sleeve gastrectomy, Roux-en-Y gastric bypass) is considered from BMI 35 regardless of complications, and from BMI 30 with metabolic disease such as type 2 diabetes.

The treatment ladder in principle

StepWhoWhat it addsWatch for
Lifestyle and behaviourEveryoneModest loss, better fitness, base for every other stepRegain without long-term support
MedicinesBMI 30 or more, or 27 or more with a complication (lower in Asian ancestry)Larger loss and fewer complications while takenGut effects, cost, regain after stopping, contraindications
Metabolic and bariatric surgeryBMI 35 or more, or 30 or more with metabolic diseaseLargest and most durable loss; diabetes remission in manyLifelong vitamin and mineral needs, dumping, late hypoglycaemia, alcohol misuse

In the clinic

  • Review the medicine list first: switching a drug that adds weight to a weight-neutral one is the cheapest treatment there is.
  • In type 2 diabetes with obesity, choose glucose-lowering drugs that lower weight (GLP-1 receptor agonists, dual agonists, SGLT2 inhibitors, metformin) over those that add it.
  • Women taking these medicines need effective contraception and should stop them before trying to conceive.
  • Adolescents with severe obesity can be offered medicines and surgery in specialised centres.
  • After bariatric surgery: lifelong supplements, yearly vitamin B12, iron, folate, calcium and vitamin D checks, and attention to post-bypass hypoglycaemia.

Next step / Initial management

  • Before treatment: glucose or HbA1c, lipids, liver enzymes, creatinine and TSH; screen complications as in the assessment page.
  • Set a realistic goal (5–15%) and the complications it should improve; review weight, waist and complications regularly.
  • Start lifestyle treatment for all; add a medicine when the BMI criteria are met; reassess benefit after a few months on a stable treatment.
  • Refer to a multidisciplinary obesity or bariatric team when BMI is 35 or more, or 30 or more with metabolic disease and poor response; refer suspected genetic obesity to endocrinology.

Common traps

  • Weight regain after stopping a medicine means it failed: obesity is chronic and the body defends its old weight, so regain on stopping shows the drug was working, as with blood pressure pills.
  • Medicines are only for people who failed diet: they are indicated by BMI and complications, and lifestyle support continues alongside them.
  • Surgery is a last resort for BMI over 40 only: current criteria start at BMI 35, or 30 with metabolic disease, because surgery gives the largest and most durable benefit.
  • Any weight loss on an incretin drug is all fat: part of the loss is lean mass, so protein intake and resistance training matter, especially in older adults.
  • Willpower is the main cause of obesity: genes, hunger hormones, sleep, medicines and environment set appetite, which is why blame does not treat it.

Test yourself

Think of the answer, then tap the question to see it.

A 45-year-old with BMI 28, type 2 diabetes and fatty liver asks whether he qualifies for an anti-obesity medicine. Does he?

Yes: BMI 27 or more with weight-related complications qualifies. A GLP-1 receptor agonist or dual agonist also helps his diabetes and liver.

A woman lost 16% of her weight on a GLP-1 receptor agonist, stopped it and regained most of it within a year. What does this show?

That obesity is chronic and the body defends its weight; the drug worked while taken. Long-term treatment is usually needed, like for hypertension.

Which history makes you avoid a GLP-1 receptor agonist?

Personal or family history of medullary thyroid carcinoma or MEN2, and pregnancy or planned pregnancy; caution with past pancreatitis.

A patient with BMI 36 and no complications asks if surgery is only for BMI over 40. What do you answer?

No: current criteria consider surgery from BMI 35 regardless of complications, because it gives the largest and most lasting weight loss.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of endocrinology

Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.

Sources: Obesity and overweight (fact sheet) (World Health Organization, 2025); Epidemiologic and Etiologic Considerations of Obesity (StatPearls (NCBI Bookshelf), 2025); Glucagon-Like Peptide-1 Receptor Agonists (StatPearls (NCBI Bookshelf), 2024); Counseling Patients on Bariatric Surgery for Obesity (StatPearls (NCBI Bookshelf), 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.